Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Inclusion Criteria:

• The participant must provide study-specific informed consent prior to any studyspecific procedures and authorization permitting release of personal healthinformation.

• The participant must have a first time diagnosis of non-metastatic breast cancerwhich is Stage I-III.

• The participant must have a score of less than 12 on the PROMIS Adult v2.0 -Cognitive Function 4a.

• Participants must be at least 6 months and no more than 5 years (after completion ofinitial surgery +/- adjuvant chemotherapy/radiation therapy) and targeted therapies (e.g., PARP inhibitors, CDK4/6, or immunotherapy). Participants may still be takingendocrine therapy and/or trastuzumab.

• The participant must be able to understand, speak, read, and write in English orSpanish.

Exclusion Criteria:

• Scoring less than or equal to 3 on the 6-item cognitive screen.

• Patient Health Questionnaire-2 item (PHQ-2) score of greater than or equal to 3.

• Definitive clinical or radiologic evidence of metastatic disease.

• Current or past history of another cancer. Patients with history of onlynon-melanoma skin cancer or in situ cervical cancer without chemotherapy treatmentwould be eligible.

• Previous exposure to chemotherapy treatment for another cancer or due to othermedical condition (e.g. methotrexate exposure for treatment of rheumatoidarthritis).

• Previous central nervous system (CNS) radiation, intrathecal therapy or CNS-involvedsurgery.

• Participants with history of stroke, traumatic brain injury, brain surgery,Alzheimer's disease or other dementia.

• Participants with active substance abuse and/or in treatment for substance abuse, orhistory of bipolar disorder, psychosis, schizophrenia, ADHD, or learning disability.

• Participants who are enrolled in an active behavioral intervention (e.g.,occupational therapy, physical therapy, etc.) or pharmaceutical intervention or whoare in the follow-up phase of a cancer control trial or therapeutic trial that hasextensive PRO follow-up after treatment ends. Participants who are enrolled in atherapeutic trial in which they have completed active treatment and require onlyminimal follow-up monitoring of toxicity and/or survival analysis (cancer-relatedmortality or all-cause mortality) would be eligible.

• Hearing impairment unless adequately corrected with hearing aids to be able to hearover the phone for the neuropsychological testing.